Welcome to our dedicated page for Veraxa Biotech SEC filings (Ticker: VRXA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Veraxa Biotech's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Veraxa Biotech's regulatory disclosures and financial reporting.
Veraxa Biotech Holding AG director Oliver Rolf Baumann filed an initial Form 3 disclosing a large indirect ownership stake. The filing reports that Akira Holding AG holds 5,723,618 Ordinary Shares, and Baumann may be deemed to beneficially own these shares through his relationship with Akira Holding AG. This is a disclosure of existing holdings rather than a new purchase or sale, giving investors a view of the director’s indirect equity interest.
Veraxa Biotech Holding AG director and Chief Executive Officer Christoph Rudiger Antz has filed an initial Form 3 as an insider of the company. The filing identifies his roles but does not report any transactions or share holdings, with all transaction and holding counts shown as zero.
Veraxa Biotech Holding AG officer Heinz Schwer has filed a Form 3 as Chief Business Officer of VRXA. This is an initial statement of beneficial ownership and shows no reported transactions, with no shares bought, sold, acquired, or disposed of in this filing.
Veraxa Biotech Holding AG executive Buergermeister Torsten Georg Friedrich, the company’s Chief Financial Officer, has filed an initial Form 3 as an officer of the company. The data provided does not list any reportable transactions or holdings, indicating this filing is primarily an initial ownership disclosure.